Kilitch Drugs (India) Share Price

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables Ophthalmic, Effervescent tablets Granules, Tablets Capsules, OTC range covering varied Nutraceuticals Cosmetics and Medical devices.The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.

Kilitch Drugs (India) reported a Q1 FY 2025-26 revenue of ₹43.14 crore, up 31.9% YoY, with net profit increased 80.9% to ₹2.26 crore. For the full year FY2025–2026, revenue reached ₹209.48 crore and profit touched at ₹24.56 crore. As of Jun '25, Kilitch Drugs (India)’s market capitalisation stood at ₹743.72 crores. Shareholding as of Jun '25 shows promoters holding 69.2%, with FIIs at 30.8%, DIIs at %, and public at %.

As of 14 Aug, 2025, Kilitch Drugs (India) share price is ₹425.4. The stock opened at ₹425.4 and had closed at ₹434.1 the previous day. During today’s trading session, Kilitch Drugs (India) share price moved between ₹425.45 and ₹425.45, with an average price for the day of ₹425.45. Over the last 52 weeks, the stock has recorded a low of ₹293.53 and a high of ₹500.00. In terms of performance, Kilitch Drugs (India) share price has increased by 40% over the past six months and has increased by 34.31% over the last year.